삼성바이오,아스트라제네카와 3천850억원 바이오의약품 생산계약

Samsung Biologics and AstraZeneca have announced a long-term global supply agreement.
The deal is valued at nearly 331 million U.S. dollars and will run through 2023.
Samsung's biotech unit will provide the large-scale commercial production of drug substances and drug products to support AstraZeneca's biologics therapeutics.
The contract price could reach almost 550 million dollars based on demand.
It will also allow AstraZeneca to expand its manufacturing capabilities into Asia.
Samsung Biologics has racked up orders worth 1.6 billion dollars so far this year.